New regulations and shifts in the economy are changing industry appetites and the tolerance of risk for investing in therapies that serve only small groups of people. In this session experts will explore current and forward-looking strategies for evaluating and investing in rare-disease research and therapeutic options that are aimed at achieving regulatory approval and access for patients.